Myriad Genetics Receives a Hold from Piper Jaffray

Piper Jaffray analyst William Quirk reiterated a Hold rating on Myriad Genetics (NASDAQ: MYGN) on November 7 and set a price target of $29. The company’s shares closed yesterday at $31.55.

According to, Quirk is a 4-star analyst with an average return of 5.3% and a 50.3% success rate. Quirk covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Accelerate Diagnostics, and Pacific Biosciences.

Myriad Genetics has an analyst consensus of Hold, with a price target consensus of $28.50.

Based on Myriad Genetics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $190 million and quarterly net profit of $81.1 million. In comparison, last year the company earned revenue of $178 million and had a GAAP net loss of $1.2 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.

Leave a Reply

Your email address will not be published. Required fields are marked *